CYP450氧化还原酶遗传多态性对CYP酶影响的研究进展

摘要/Abstract

摘要： 细胞色素P450氧化还原酶(Cytochrome P450 oxidoreductase, POR)是将电子从NADPH转运至所有肝微粒体的细胞色素P450氧化酶(Cytochrome P450 monooxygenases,CYP)中的唯一供体。药物、类固醇激素等物质的代谢和转化需要CYP参与。POR基因具有遗传多态性,遗传变异可以改变CYP活性,引起P450氧化还原酶缺陷(P450 oxidoreductase deficiency,PORD)、临床药物代谢和反应差异。本文将从POR的结构功能、基因突变引起的疾病及其对酶活性影响三个方面进行论述,总结近年来POR遗传多态性对CYP酶影响的最新研究进展。

关键词: CYP450氧化还原酶, 细胞色素P450氧化酶, P450氧化还原酶缺陷, 遗传多态, 基因突变

Abstract: Cytochrome P450 oxidoreductase (POR) is the only electron dornor for transferring electrons from NADPH to all microsome Cytochrome P450 monooxygenases(CYP).CYP is involved in the metabolism and transformation of drugs ,steroids and other substances. Polymorphisms and genetic variations of POR change the activity of CYP, resulting in P450 oxidoreductase deficiency (PORD), differences on drug metabolism and reaction. The review summarizes the recent research progress on influence of POR genetic polymorphisms on CYP from three parts: structure and function, disease and influence on enzymes.

Key words: Cytochrome P450 oxidoreductase, Cytochrome P450 monooxygenases, P450 oxidoreductase deficiency, Genetic polymorphism, Genetic variation

中图分类号:

R968

黄路, 阳国平. CYP450氧化还原酶遗传多态性对CYP酶影响的研究进展[J]. 中国临床药理学与治疗学, 2013, 18(7): 818-823.

HUANG Lu, YANG Guo-ping. Progress on influence of cytochrome P450 oxidoreductase polymorphisms on cytochrome P450 monoxyfenases[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(7): 818-823.

参考文献

[1] 胡蕾, 高利臣, 卓伟,等.CYP450氧化还原酶的药物基因组学研究进展[J].中国临床药理学与治疗学, 2012,17(7): 820-827.
[2] Gutierrez A, Grunau A, Paine M,et al. Electron transfer in human cytochrome P450 reductase[J].Biochem Soc Trans, 2003, 31(Pt 3): 497-501.
[3] Fluck CE, Mullis PE, Pandey AV. Modeling of human P450 oxidoreductase structure by in silico mutagenesis and MD simulation[J].Mol Cell Endocrinol, 2009, 313(1/2): 17-22.
[4] Xia C, Hamdane D, Shen AL,et al. Conformational changes of NADPH-cytochrome P450 oxidoreductase are essential for catalysis and cofactor binding[J].J Biol Chem, 2011, 286(18): 16246-16260.
[5] Xia C, Panda SP, Marohnic CC,et al. Structural basis for human NADPH-cytochrome P450 oxidoreductase deficiency[J].Proc Natl Acad Sci USA, 2011, 108(33): 13486-13491.
[6] Feidt DM, Klein K, Nussler A,et al. RNA-interference approach to study functions of NADPH : cytochrome P450 oxidoreductase in human hepatocytes[J].Chem Biodivers, 2009, 6(11): 2084-2091.
[7] Polusani SR, Kar R, Riquelme MA,et al. Regulation of gap junction function and Connexin 43 expression by cytochrome P450 oxidoreductase (CYPOR)[J].Biochem Biophys Res Commun, 2011, 411(3): 490-495.
[8] Hall CN, Keynes RG, Garthwaite J. Cytochrome P450 oxidoreductase participates in nitric oxide consumption by rat brain[J].Biochem J, 2009, 419(2): 411-418.
[9] Huang N, Agrawal V, Giacomini KM, et al. Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations[J].Proc Natl Acad Sci USA, 2008, 105(5): 1733-1738.
[10] Agrawal V, Huang N, Miller WL. Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19[J].Pharmacogenet Genomics, 2008, 18(7): 569-576.
[11] Zeng WT, Zheng QS, Huang M,et al. Genetic polymorphisms of VKORC1, CYP2C9, CYP4F2 in Bai, Tibetan Chinese[J].Pharmazie, 2012, 67(1): 69-73.
[12] Saito Y, Yamamoto N, Katori N,et al. Genetic polymorphisms and haplotypes of por, encoding cytochrome p450 oxidoreductase, in a Japanese population[J].Drug Metab Pharmacokinet, 2011, 26(1): 107-116.
[13] Fluck CE, Mallet D, Hofer G,et al.Deletion of P399_E401 in NADPH cytochrome P450 oxidoreductase results in partial mixed oxidase deficiency[J].Biochem Biophys Res Commun, 2011, 412(4): 572-577.
[14] Scott RR, Miller WL. Genetic and clinical features of p450 oxidoreductase deficiency[J].Horm Res, 2008, 69(5): 266-275.
[15] But WM, Lo IF, Shek CC,et al. Ambiguous genitalia, impaired steroidogenesis, and Antley-Bixler syndrome in a patient with P450 oxidoreductase deficiency[J].Hong Kong Med J, 2010, 16(1): 59-62.
[16] Miller WL, Agrawal V, Sandee D,et al. Consequences of POR mutations and polymorphisms[J].Mol Cell Endocrinol, 2011, 336(1/2): 174-179.
[17] Krone N, Reisch N, Idkowiak J,et al. Genotype-phenotype analysis in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency[J].J Clin Endocrinol Metab, 2012, 97(2): E257-E267.
[18] Alberola TM, Bautista-Llacer R, Fernandez E,et al. Preimplantation genetic diagnosis of P450 oxidoreductase deficiency and Huntington Disease using three different molecular approaches simultaneously[J].J Assist Reprod Genet, 2009, 26(5): 263-271.
[19] Tomalik-Scharte D, Maiter D, Kirchheiner J,et al. Impaired hepatic drug and steroid metabolism in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency[J].Eur J Endocrinol, 2010, 163(6): 919-924.
[20] Gomes LG, Huang N, Agrawal V,et al. The common P450 oxidoreductase variant A503V is not a modifier gene for 21-Hydroxylase deficiency[J]. J Clin Endocrinol Metab, 2008, 93(7): 2913-2916.
[21] Gomes AM, Winter S, Klein K,et al. Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation[J].Pharmacogenomics, 2009, 10(4): 579-599.
[22] Oneda B, Crettol S, Jaquenoud SE,et al. The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test[J].Pharmacogenet Genomics, 2009, 19(11): 877-883.
[23] de Jonge H, Metalidis C, Naesens M,et al. The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients[J].Pharmacogenomics, 2011, 12(9): 1281-1291.
[24] Yang G, Fu Z, Chen X,et al. Effects of the CYP oxidoreductase Ala503Val polymorphism on CYP3A activity in vivo: a randomized, open-label, crossover study in healthy Chinese men[J].Clin Ther, 2011, 33(12): 2060-2070.
[25] Agrawal V, Choi JH, Giacomini KM,et al. Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase[J].Pharmacogenet Genomics, 2010, 20(10): 611-618.
[26] Fluck CE, Mullis PE, Pandey AV. Reduction in hepatic drug metabolizing CYP3A4 activities caused by P450 oxidoreductase mutations identified in patients with disordered steroid metabolism[J].Biochem Biophys Res Commun, 2010, 401(1): 149-153.
[27] Nicolo C, Fluck CE, Mullis PE,et al. Restoration of mutant cytochrome P450 reductase activity by external flavin[J].Mol Cell Endocrinol, 2010, 321(2): 245-252.
[28] Moutinho D, Marohnic CC, Panda SP,et al. Altered human CYP3A4 activity caused by Antley-Bixler syndrome-related variants of NADPH-cytochrome P450 oxidoreductase measured in a robust in vitro system[J].Drug Metab Dispos, 2012, 40(4): 754-760.
[29] Sandee D, Morrissey K, Agrawal V,et al. Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro[J].Pharmacogenet Genomics, 2010, 20(11): 677-686.
[30] Lim JS, Chen XA, Singh O,et al. Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients[J].Br J Clin Pharmacol, 2011, 71(5): 737-750.
[31] Lee JB, Lee KA, Lee KY.Cytochrome P450 2C19 polymorphism is associated with reduced clopidogrel response in cerebrovascular disease[J].Yonsei Med J, 2011, 52(5): 734-738.
[32] Zi J, Liu D, Ma P,et al. Effects of CYP2C9^*3 and CYP2C9*13 on diclofenac metabolism and inhibition-based drug-drug interactions[J].Drug Metab Pharmacokinet, 2010, 25(4): 343-350.
[33] Zhang X, Li L, Ding X,et al. Identification of cytochrome P450 oxidoreductase gene variants that are significantly associated with the interindividual variations in warfarin maintenance dose[J]. Drug Metab Dispos, 2011, 39(8): 1433-1439.
[34] 曾婷, 陈苏红, 刘志红,等.华法林药物基因组学的研究推动其个体化医疗的进程[J].中国药理学与毒理学杂志, 2009,24(2): 146-151.
[35] Marohnic CC, Panda SP, McCammon K,et al. Human cytochrome P450 oxidoreductase deficiency caused by the Y181D mutation: molecular consequences and rescue of defect[J].Drug Metab Dispos, 2010, 38(2): 332-340.
[36] Soneda S, Yazawa T, Fukami M,et al. Proximal promoter of the cytochrome P450 oxidoreductase gene: identification of microdeletions involving the untranslated exon 1 and critical function of the SP1 binding sites[J].J Clin Endocrinol Metab, 2011, 96(11): E1881-E1887.
[37] Zawaira A, Gallotta M, Beeton-Kempen N,et al. Exhaustive computational search of ionic-charge clusters that mediate interactions between mammalian cytochrome P450 (CYP) and P450-oxidoreductase (POR) proteins[J].Comput Biol Chem, 2010, 34(1): 42-52.